iCAD, Inc., announced today the unveiling of a new computer-aided detection (CAD) tool designed for use in digital breast tomosynthesis.
According to the company, this cancer detection solution is an industry first, with the capability to analyze multiple images and data sets and blend them into a single composite view, saving time and improving efficiency for reading radiologists.
"The launch of this powerful solution demonstrates our commitment to remain on the forefront of cancer detection and workflow efficiency," said iCAD CEO Ken Ferry in a press release. "Cancer detection solutions have proven to be effective for 2D mammography in assisting radiologists to identify cancer in earlier stages, when it may be more effectively treated. We believe our concurrent read software for breast tomosynthesis will change how radiologists read tomosynthesis studies creating an improved reading experience and a more efficient workflow while also aiding in the detection of cancer."
The technology, which will be introduced initially in European markets, is currently on display in the company’s booth at the European Congress of Radiology meeting in Vienna, Austria, and is expected to receive FDA clearance in late 2016.